Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: The dose applied regulates the expansion of the response

Immunology

Volumn 110, Issue 4, 2003, Pages 474-481

  Sartoris, Silvia ^a,c   Testi, Maria G ^a   Stefani, Elisabetta ^a   Chignola, Roberto ^a   Guerriero, Chiara ^a   Matucci, Andrea ^a   Cestari, Tiziana ^a   Scarpa, Aldo ^a   Riviera, Anna P ^b   Zanoni, Giovanna ^b   Tridente, Giuseppe ^a   Andrighetto, Giancarlo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c c/o Policlinico GB Rossi ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER INCIDENCE; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; FEMALE; HYBRIDOMA; IMMUNIZATION; IMMUNOGENICITY; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD80; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FLOW CYTOMETRY; HYBRIDOMAS; IMMUNIZATION; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LYMPH NODES; MICE; MICE, INBRED BALB C; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 10744233212     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2003.01760.x     Document Type: Article

References (26)

1. Schreiber H. Tumor immunology. In: Paul WE, ed. Fundamental Immunology. Philadelphia: Lippincott-Raven Publishers. 1999:1237-70.
2. Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000; 12:571-5.
3. Ostrand-Rosenberg S, Pulaski BA, Clemens VK, Qi L, Pipeling MR, Hanyok LA. Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev 1999; 170:101-14.
4. Allison JP, Hurwitz AA, Leach DA. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995; 7:682-6.
5. Hurwitz A, Kwon EO, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol 2000; 12:589-96.
6. Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol 2002; 23:240-5.
7. Cavallo F, Martin-Fontecha A, Bellone M et al. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 1995; 25:1154-62.
8. Wu T-C, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995; 182:1415-21.
9. Chong H, Hutchinson G, Hart IR, Vile RG. Expression of B7 costimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumor response, but induces T-cell-dependent systemic immunity only against B7-expressing tumors. Br J Cancer 1998; 78:1043-50,
10. + T cells by B7-transfected melanoma cells. Science 1993; 259:368-70.
11. Schoenberger SP, Jonges LE, Mooijaart JD, Hartgers F, Toes REM, Kast MW, Melief CJM, Offringa R. Efficient direct priming of tumor-specific cytotoxic T lymphocytes in vivo by an engineered APC. Cancer Res 1998; 58:3094-100.
12. Guilloux Y, Bai X, Liu X, Zheng P, Liu Y. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res 2001; 61:1107-12.
13. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994; 179:1205-14.
14. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997; 156:199-209.
15. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001; 293:251-3.
16. Ochsenbein AF. Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther 2002; 9:1043-55.
17. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999; 96:2233-8.
18. Koehler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 1976; 6:511-9.
19. Chignola R, Anselmi C, Franceschi A, Pasti M, Candiani C, Tridente G, Colombatti M. Sensitivity of human leukemia cells in exponential or stationary growth phase to anti-CD5 immunotoxins. J Immunol 1994; 152:2333-43.
20. Cayeux S, Qin Z, Dörken B, Blankenstein T. Decreased generation of anti-tumor immunity after intrasplenic immunization. Eur J Immunol 2001; 31:1392-9.
21. Joki T, Kikuchi T, Akasaki Y, Saitoh S, Abe T, Ohno T. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin-12. Int J Cancer 1999; 82:714-20.
22. Zheng P, Sarma S, Guo Y, Liu Y. Two mechanisms for tumor evasion of preexisting cytotoxic T cell responses: lessons from recurrent tumors. Cancer Res 1999; 59:3461-7.
23. Gaiewski TF, Fallarino F, Uyttenhove C, Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor. J Immunol 1996; 156:2909-17.
24. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996; 183:769-76.
25. Ochsenbein AF, Sierro S, Odermatt B et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411:1058-64.
26. Haanen JBAG, Toebes M, Cordaro TA, Wolkers MC, Kruisbeek AM, Schumacher TNM. Systemic T cell expansion during localized viral infection. Eur J Immunol 1999; 29:1168-74.